{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:26:13Z","timestamp":1792844773301,"version":"4.5.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100005026","name":"Stichting Tegen Kanker","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["1095969"],"award-info":[{"award-number":["1095969"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["111424"],"award-info":[{"award-number":["111424"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["GCB120981SAN"],"award-info":[{"award-number":["GCB120981SAN"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13045-017-0549-1","type":"journal-article","created":{"date-parts":[[2018,1,16]],"date-time":"2018-01-16T12:51:45Z","timestamp":1516107105000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":303,"title":["Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3175-1195","authenticated-orcid":false,"given":"J.","family":"Caers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Paiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Zamagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Leleu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Blad\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Y.","family":"Kristinsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Touzeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Abildgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Heusschen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Ocio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Delforge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Sezer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Beksac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Merlini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Zweegman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Rosi\u00f1ol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,16]]},"reference":[{"key":"549_CR1","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M-V, Kumar S, Hillengass J, Kastritis E, Richardson P, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538\u201348.","journal-title":"Lancet Oncol"},{"key":"549_CR2","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood.V96.6.2037","volume":"96","author":"MA Dimopoulos","year":"2000","unstructured":"Dimopoulos MA, Moulopoulos LA, Maniatis A, Alexanian R. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood. 2000;96:2037\u201344.","journal-title":"Blood"},{"key":"549_CR3","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0167-8140(99)00114-0","volume":"52","author":"RH Liebross","year":"1999","unstructured":"Liebross RH, Ha CS, Cox JD, Weber D, Delasalle K, Alexanian R. Clinical course of solitary extramedullary plasmacytoma. Radiother Oncol. 1999;52:245\u20139.","journal-title":"Radiother Oncol"},{"key":"549_CR4","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/ejh.12907","volume":"99","author":"H Nahi","year":"2017","unstructured":"Nahi H, Genell A, Walinder G, Uttervall K, Juliusson G, Karin F, Hansson M, Svensson R, Linder O, Carlson K, et al. Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register. Eur J Haematol. 2017;99:216\u201322.","journal-title":"Eur J Haematol"},{"key":"549_CR5","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ijrobp.2005.06.039","volume":"64","author":"M Ozsahin","year":"2006","unstructured":"Ozsahin M, Tsang RW, Poortmans P, Belkacemi Y, Bolla M, Dincbas FO, Landmann C, Castelain B, Buijsen J, Curschmann J, et al. Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients. Int J Radiat Oncol Biol Phys. 2006;64:210\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"549_CR6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1100\/2012\/895765","volume":"2012","author":"S Kilciksiz","year":"2012","unstructured":"Kilciksiz S, Karakoyun-Celik O, Agaoglu FY, Haydaroglu A. A review for solitary plasmacytoma of bone and extramedullary plasmacytoma. Sci World J. 2012;2012:6.","journal-title":"Sci World J"},{"key":"549_CR7","first-page":"373","volume":"2005","author":"DM Weber","year":"2005","unstructured":"Weber DM. Solitary bone and extramedullary plasmacytoma. ASH Education Program Book. 2005;2005:373\u20136.","journal-title":"ASH Education Program Book"},{"key":"549_CR8","doi-asserted-by":"publisher","first-page":"623","DOI":"10.3324\/haematol.12005","volume":"93","author":"K Bink","year":"2008","unstructured":"Bink K, Haralambieva E, Kremer M, Ott G, Beham-Schmid C, de Leval L, Peh SC, Laeng HR, J\u00fctting U, Hutzler P, et al. Primary extramedullary plasmacytoma: similarities with and differences from multiple myeloma revealed by interphase cytogenetics. Haematologica. 2008;93:623\u20136.","journal-title":"Haematologica"},{"key":"549_CR9","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/j.1365-2141.2010.08386.x","volume":"151","author":"M Boll","year":"2010","unstructured":"Boll M, Parkins E, O\u2019Connor SJM, Rawstron AC, Owen RG. Extramedullary plasmacytoma are characterized by a \u2018myeloma-like\u2019 immunophenotype and genotype and occult bone marrow involvement. Br J Haematol. 2010;151:525\u20137.","journal-title":"Br J Haematol"},{"key":"549_CR10","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1182\/blood-2014-04-566521","volume":"124","author":"QA Hill","year":"2014","unstructured":"Hill QA, Rawstron AC, de Tute RM, Owen RG. Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis. Blood. 2014;124:1296\u20139.","journal-title":"Blood"},{"key":"549_CR11","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1182\/blood-2014-04-567909","volume":"124","author":"B Paiva","year":"2014","unstructured":"Paiva B, Chandia M, Vidriales M-B, Colado E, Caballero-Vel\u00e1zquez T, Escalante F, Garcia de Coca A, Montes M-C, Garcia-Sanz R, Ocio EM, et al. Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma. Blood. 2014;124:1300\u20133.","journal-title":"Blood"},{"key":"549_CR12","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1080\/10428190600647723","volume":"47","author":"MA Dimopoulos","year":"2006","unstructured":"Dimopoulos MA, Pouli A, Anagnostopoulos A, Repoussis P, Symeonidis A, Terpos E, Delimbasi S, Tsolakis F, Economopoulos T, Zervas C. Macrofocal multiple myeloma in young patients: a distinct entity with favorable prognosis. Leuk Lymphoma. 2006;47:1553\u20136.","journal-title":"Leuk Lymphoma"},{"key":"549_CR13","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1038\/leu.2012.120","volume":"26","author":"JJM van Dongen","year":"2012","unstructured":"van Dongen JJM, Lhermitte L, Bottcher S, Almeida J, van der Velden VHJ, Flores-Montero J, Rawstron A, Asnafi V, Lecrevisse Q, Lucio P, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26:1908\u201375.","journal-title":"Leukemia"},{"key":"549_CR14","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1148\/rg.284075156","volume":"28","author":"MH Rodallec","year":"2008","unstructured":"Rodallec MH, Feydy A, Larousserie F, Anract P, Campagna R, Babinet A, Zins M, Drape JL. Diagnostic imaging of solitary tumors of the spine: what to do and say. Radiographics. 2008;28:1019\u201341.","journal-title":"Radiographics"},{"key":"549_CR15","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3324\/haematol.2013.091918","volume":"99","author":"J Caers","year":"2014","unstructured":"Caers J, Withofs N, Hillengass J, Simoni P, Zamagni E, Hustinx R, Beguin Y. The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma. Haematologica. 2014;99:629\u201337.","journal-title":"Haematologica"},{"key":"549_CR16","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/S0009-9260(67)80010-2","volume":"18","author":"GA Edelstyn","year":"1967","unstructured":"Edelstyn GA, Gillespie PJ, Grebbell FS. The radiological demonstration of osseous metastases. Experimental observations. Clin Radiol. 1967;18:158\u201362.","journal-title":"Clin Radiol"},{"key":"549_CR17","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1097\/01.rct.0000237820.41549.c9","volume":"31","author":"J Hur","year":"2007","unstructured":"Hur J, Yoon CS, Ryu YH, Yun MJ, Suh JS. Efficacy of multidetector row computed tomography of the spine in patients with multiple myeloma: comparison with magnetic resonance imaging and fluorodeoxyglucose-positron emission tomography. J Comput Assist Tomogr. 2007;31:342\u20137.","journal-title":"J Comput Assist Tomogr"},{"key":"549_CR18","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.2214\/AJR.07.2635","volume":"190","author":"A Baur-Melnyk","year":"2008","unstructured":"Baur-Melnyk A, Buhmann S, Becker C, Schoenberg SO, Lang N, Bartl R, Reiser MF. Whole-body MRI versus whole-body MDCT for staging of multiple myeloma. Am J Roentgenol. 2008;190:1097\u2013104.","journal-title":"Am J Roentgenol"},{"key":"549_CR19","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00256-008-0607-4","volume":"38","author":"TG Gleeson","year":"2009","unstructured":"Gleeson TG, Moriarty J, Shortt CP, Gleeson JP, Fitzpatrick P, Byrne B, McHugh J, O'Connell M, O'Gorman P, Eustace SJ. Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole-body MRI (WBMRI). Skelet Radiol. 2009;38:225\u201336.","journal-title":"Skelet Radiol"},{"key":"549_CR20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00330-007-0738-3","volume":"18","author":"P Kropil","year":"2008","unstructured":"Kropil P, Fenk R, Fritz LB, Blondin D, Kobbe G, Modder U, Cohnen M. Comparison of whole-body 64-slice multidetector computed tomography and conventional radiography in staging of multiple myeloma. Eur Radiol. 2008;18:51\u20138.","journal-title":"Eur Radiol"},{"key":"549_CR21","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ejrad.2004.04.015","volume":"54","author":"M Horger","year":"2005","unstructured":"Horger M, Claussen CD, Bross-Bach U, Vonthein R, Trabold T, Heuschmid M, Pfannenberg C. Whole-body low-dose multidetector row-CT in the diagnosis of multiple myeloma: an alternative to conventional radiography. Eur J Radiol. 2005;54:289\u201397.","journal-title":"Eur J Radiol"},{"key":"549_CR22","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","volume":"100","author":"E Terpos","year":"2015","unstructured":"Terpos E, Kleber M, Engelhardt M, Zweegman S, Gay F, Kastritis E, van de Donk NWCJ, Bruno B, Sezer O, Broijl A, et al. European Myeloma Network guidelines for the management of multiple myeloma-related complications. Haematologica. 2015;100:1254\u201366.","journal-title":"Haematologica"},{"key":"549_CR23","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1200\/JCO.1993.11.7.1311","volume":"11","author":"LA Moulopoulos","year":"1993","unstructured":"Moulopoulos LA, Dimopoulos MA, Weber D, Fuller L, Libshitz HI, Alexanian R. Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. J Clin Oncol. 1993;11:1311\u20135.","journal-title":"J Clin Oncol"},{"key":"549_CR24","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/S0360-3016(98)00186-2","volume":"41","author":"RH Liebross","year":"1998","unstructured":"Liebross RH, Ha CS, Cox JD, Weber D, Delasalle K, Alexanian R. Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy. Int J Radiat Oncol Biol Phys. 1998;41:1063\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"549_CR25","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1200\/JCO.2014.57.9961","volume":"33","author":"MA Dimopoulos","year":"2015","unstructured":"Dimopoulos MA, Hillengass J, Usmani S, Zamagni E, Lentzsch S, Davies FE, Raje N, Sezer O, Zweegman S, Shah J, et al. Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. J Clin Oncol. 2015;33:657\u201364.","journal-title":"J Clin Oncol"},{"key":"549_CR26","doi-asserted-by":"publisher","first-page":"3254","DOI":"10.1158\/1078-0432.CCR-13-2910","volume":"20","author":"G Fouquet","year":"2014","unstructured":"Fouquet G, Guidez S, Herbaux C, Van de Wyngaert Z, Bonnet S, Beauvais D, Demarquette H, Adib S, Hivert B, Wemeau M, et al. Impact of initial FDG-PET\/CT and serum-free light chain on transformation of conventionally defined solitary plasmacytoma to multiple myeloma. Clin Cancer Res. 2014;20:3254\u201360.","journal-title":"Clin Cancer Res"},{"key":"549_CR27","first-page":"513","volume":"22","author":"C Nanni","year":"2008","unstructured":"Nanni C, Rubello D, Zamagni E, Castellucci P, Ambrosini V, Montini G, Cavo M, Lodi F, Pettinato C, Grassetto G, et al. 18F-FDG PET\/CT in myeloma with presumed solitary plasmocytoma of bone. In Vivo. 2008;22:513\u20137.","journal-title":"In Vivo"},{"key":"549_CR28","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1089\/108497803770418382","volume":"18","author":"H Schirrmeister","year":"2003","unstructured":"Schirrmeister H, Buck AK, Bergmann L, Reske SN, Bommer M. Positron emission tomography (PET) for staging of solitary plasmacytoma. Cancer Biother Radiopharm. 2003;18:841\u20135.","journal-title":"Cancer Biother Radiopharm"},{"key":"549_CR29","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.ijrobp.2008.08.037","volume":"74","author":"PJ Kim","year":"2009","unstructured":"Kim PJ, Hicks RJ, Wirth A, Ryan G, Seymour JF, Prince HM, Mac Manus MP. Impact of 18F-fluorodeoxyglucose positron emission tomography before and after definitive radiation therapy in patients with apparently solitary plasmacytoma. Int J Radiat Oncol Biol Phys. 2009;74:740\u20136.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"549_CR30","volume-title":"FDG-positron-emission tomography for staging and therapeutic assessment in patients with plasmacytoma","author":"P-Y Salaun","year":"2008","unstructured":"Salaun P-Y, Gastinne T, Frampas E, Bodet-Milin C, Moreau P, Bod\u00e9r\u00e9-Kraeber F: FDG-positron-emission tomography for staging and therapeutic assessment in patients with plasmacytoma. 2008."},{"key":"549_CR31","doi-asserted-by":"crossref","unstructured":"Albano D, Bosio G, Treglia G, Giubbini R, Bertagna F. 18F\u2013FDG PET\/CT in solitary plasmacytoma: metabolic behavior and progression to multiple myeloma. Eur J Nucl Med Mol Imaging. 2018;45(1):77-84.","DOI":"10.1007\/s00259-017-3810-5"},{"key":"549_CR32","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","volume":"18","author":"M Cavo","year":"2017","unstructured":"Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, Hillengass J, Engelhardt M, Usmani SZ, Vesole DH, et al. Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017;18:e206\u201317.","journal-title":"Lancet Oncol"},{"key":"549_CR33","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1002\/(SICI)1097-0142(19990601)85:11<2305::AID-CNCR2>3.0.CO;2-3","volume":"85","author":"C Alexiou","year":"1999","unstructured":"Alexiou C, Kau RJ, Dietzfelbinger H, Kremer M, Spie\u00df JC, Schratzenstaller B, Arnold W. Extramedullary plasmacytoma. Cancer. 1999;85:2305\u201314.","journal-title":"Cancer"},{"key":"549_CR34","volume-title":"Clinical outcome of extramedullary plasmacytoma","author":"P Galieni","year":"2000","unstructured":"Galieni P, Cavo M, Pulsoni A, Avvisati G, Bigazzi C, Neri S, Caliceti U, Benni M, Ronconi S, Lauria F: Clinical outcome of extramedullary plasmacytoma. 2000."},{"key":"549_CR35","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1365-2141.2008.07421.x","volume":"144","author":"GM Dores","year":"2009","unstructured":"Dores GM, Landgren O, McGlynn KA, Curtis RE, Linet MS, Devesa SS. Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992\u20132004. Br J Haematol. 2009;144:86\u201394.","journal-title":"Br J Haematol"},{"key":"549_CR36","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/bjh.14291","volume":"175","author":"EG de Waal","year":"2016","unstructured":"de Waal EG, Leene M, Veeger N, Vos HJ, Ong F, Smit WG, Hovenga S, Hoogendoorn M, Hogenes M, Beijert M, et al. Progression of a solitary plasmacytoma to multiple myeloma. A population-based registry of the northern Netherlands. Br J Haematol. 2016;175:661\u20137.","journal-title":"Br J Haematol"},{"key":"549_CR37","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/ajh.23201","volume":"87","author":"R Warsame","year":"2012","unstructured":"Warsame R, Gertz MA, Lacy MQ, Kyle RA, Buadi F, Dingli D, Greipp PR, Hayman SR, Kumar SK, Lust JA, et al. Trends and outcomes of modern staging of solitary plasmacytoma of bone. Am J Hematol. 2012;87:647\u201351.","journal-title":"Am J Hematol"},{"key":"549_CR38","doi-asserted-by":"crossref","unstructured":"Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, Palumbo A, Jagannath S, Blade J, Lonial S, Dimopoulos M, Comenzo R, Einsele H, Barlogie B, Anderson K, Gertz M, Harousseau JL, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Richardson P, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Rajkumar SV, Durie BG, International Myeloma Working Group. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009;23(2):215-24.","DOI":"10.1038\/leu.2008.307"},{"key":"549_CR39","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3109\/07853890.2013.801562","volume":"45","author":"J Caers","year":"2013","unstructured":"Caers J, Vekemans M-C, Bries G, Beel K, Delrieu V, Deweweire A, Demuynck H, De Prijck B, De Samblanx H, Kentos A, et al. Diagnosis and follow-up of monoclonal gammopathies of undetermined significance; information for referring physicians. Ann Med. 2013;45:413\u201322.","journal-title":"Ann Med"},{"key":"549_CR40","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/bjc.1997.162","volume":"75","author":"SS Susnerwala","year":"1997","unstructured":"Susnerwala SS, Shanks JH, Banerjee SS, Scarffe JH, Farrington WT, Slevin NJ. Extramedullary plasmacytoma of the head and neck region: clinicopathological correlation in 25 cases. Br J Cancer. 1997;75:921\u20137.","journal-title":"Br J Cancer"},{"key":"549_CR41","volume-title":"Prognostic value of angiogenesis in solitary bone plasmacytoma","author":"S Kumar","year":"2003","unstructured":"Kumar S, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Wellik L, Witzig TE, Gertz MA, Kyle RA, Greipp PR, Rajkumar SV: Prognostic value of angiogenesis in solitary bone plasmacytoma. 2003."},{"key":"549_CR42","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1002\/cncr.10366","volume":"94","author":"RB Wilder","year":"2002","unstructured":"Wilder RB, Ha CS, Cox JD, Weber D, Delasalle K, Alexanian R. Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone. Cancer. 2002;94:1532\u20137.","journal-title":"Cancer"},{"key":"549_CR43","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1002\/1097-0142(19920315)69:6<1513::AID-CNCR2820690633>3.0.CO;2-X","volume":"69","author":"J Holland","year":"1992","unstructured":"Holland J, Trenkner DA, Wasserman TH, Fineberg B. Plasmacytoma. Treatment results and conversion to myeloma. Cancer. 1992;69:1513\u20137.","journal-title":"Cancer"},{"key":"549_CR44","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1182\/blood-2006-04-015784","volume":"108","author":"D Dingli","year":"2006","unstructured":"Dingli D, Kyle RA, Rajkumar SV, Nowakowski GS, Larson DR, Bida JP, Gertz MA, Therneau TM, Melton LJ 3rd, Dispenzieri A, Katzmann JA. Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood. 2006;108:1979\u201383.","journal-title":"Blood"},{"key":"549_CR45","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/ajh.21211","volume":"83","author":"S Kilciksiz","year":"2008","unstructured":"Kilciksiz S, Celik OK, Pak Y, Demiral AN, Pehlivan M, Orhan O, Tokatli F, Agaoglu F, Zincircioglu B, Atasoy BM, et al. Clinical and prognostic features of plasmacytomas: a multicenter study of Turkish Oncology Group-Sarcoma Working Party. Am J Hematol. 2008;83:702\u20137.","journal-title":"Am J Hematol"},{"key":"549_CR46","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/1471-2407-6-118","volume":"6","author":"D Knobel","year":"2006","unstructured":"Knobel D, Zouhair A, Tsang RW, Poortmans P, Belkacemi Y, Bolla M, Oner FD, Landmann C, Castelain B, Ozsahin M. Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study. BMC Cancer. 2006;6:118.","journal-title":"BMC Cancer"},{"key":"549_CR47","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0360-3016(00)01572-8","volume":"50","author":"RW Tsang","year":"2001","unstructured":"Tsang RW, Gospodarowicz MK, Pintilie M, Bezjak A, Wells W, Hodgson DC, Stewart AK. Solitary plasmacytoma treated with radiotherapy: impact of tumor size on outcome. Int J Radiat Oncol Biol Phys. 2001;50:113\u201320.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"549_CR48","doi-asserted-by":"publisher","first-page":"4468","DOI":"10.1002\/cncr.26031","volume":"117","author":"V Reed","year":"2011","unstructured":"Reed V, Shah J, Medeiros LJ, Ha CS, Mazloom A, Weber DM, Arzu IY, Orlowski RZ, Thomas SK, Shihadeh F, et al. Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy. Cancer. 2011;117:4468\u201374.","journal-title":"Cancer"},{"key":"549_CR49","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/j.1365-2141.2004.04834.x","volume":"124","author":"R Soutar","year":"2004","unstructured":"Soutar R, Lucraft H, Jackson G, Reece A, Bird J, Low E, Samson D. Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Br J Haematol. 2004;124:717\u201326.","journal-title":"Br J Haematol"},{"key":"549_CR50","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/(SICI)1099-1069(199609)14:3<111::AID-HON575>3.0.CO;2-G","volume":"14","author":"A Aviles","year":"1996","unstructured":"Aviles A, Huerta-Guzman J, Delgado S, Fernandez A, Diaz-Maqueo JC. Improved outcome in solitary bone plasmacytomata with combined therapy. Hematol Oncol. 1996;14:111\u20137.","journal-title":"Hematol Oncol"},{"key":"549_CR51","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/bjc.1995.26","volume":"71","author":"LY Shih","year":"1995","unstructured":"Shih LY, Dunn P, Leung WM, Chen WJ, Wang PN. Localised plasmacytomas in Taiwan: comparison between extramedullary plasmacytoma and solitary plasmacytoma of bone. Br J Cancer. 1995;71:128\u201333.","journal-title":"Br J Cancer"},{"key":"549_CR52","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S0360-3016(96)00334-3","volume":"36","author":"TW Bolek","year":"1996","unstructured":"Bolek TW, Marcus RB Jr, Mendenhall NP. Solitary plasmacytoma of bone and soft tissue. Int J Radiat Oncol Biol Phys. 1996;36:329\u201333.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"549_CR53","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/j.1600-0609.2004.00404.x","volume":"74","author":"E Jantunen","year":"2005","unstructured":"Jantunen E, Koivunen E, Putkonen M, Siitonen T, Juvonen E, Nousiainen T. Autologous stem cell transplantation in patients with high-risk plasmacytoma. Eur J Haematol. 2005;74:402\u20136.","journal-title":"Eur J Haematol"},{"key":"549_CR54","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1200\/JCO.2012.47.7901","volume":"31","author":"E Terpos","year":"2013","unstructured":"Terpos E, Morgan G, Dimopoulos MA, Drake MT, Lentzsch S, Raje N, Sezer O, Garc\u00eda-Sanz R, Shimizu K, Turesson I, et al. International Myeloma Working Group recommendations for the treatment of multiple myeloma\u2013related bone disease. J Clin Oncol. 2013;31:2347\u201357.","journal-title":"J Clin Oncol"},{"key":"549_CR55","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1002\/cncr.23783","volume":"113","author":"P Musto","year":"2008","unstructured":"Musto P, Petrucci MT, Bringhen S, Guglielmelli T, Caravita T, Bongarzoni V, Andriani A, D\u2019Arena G, Balleari E, Pietrantuono G, et al. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer. 2008;113:1588\u201395.","journal-title":"Cancer"},{"key":"549_CR56","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467\u201373.","journal-title":"Leukemia"},{"key":"549_CR57","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"549_CR58","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","volume":"117","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, Blade J, Richardson P, Orlowski R, Siegel D, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117:4691\u20135.","journal-title":"Blood"},{"key":"549_CR59","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1634\/theoncologist.2015-0303","volume":"21","author":"J Caers","year":"2016","unstructured":"Caers J, Fernandez de Larrea C, Leleu X, Heusschen R, Zojer N, Decaux O, Kastritis E, Minnema M, Jurczyszyn A, Beguin Y, et al. The changing landscape of smoldering multiple myeloma: a European perspective. Oncologist. 2016;21:333\u201342.","journal-title":"Oncologist"},{"key":"549_CR60","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1056\/NEJMoa1300439","volume":"369","author":"M-V Mateos","year":"2013","unstructured":"Mateos M-V, Hern\u00e1ndez M-T, Giraldo P, de la Rubia J, de Arriba F, Corral LL, Rosi\u00f1ol L, Paiva B, Palomera L, Bargay J, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med. 2013;369:438\u201347.","journal-title":"N Engl J Med"},{"key":"549_CR61","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/ajh.23745","volume":"89","author":"E Katodritou","year":"2014","unstructured":"Katodritou E, Terpos E, Symeonidis AS, Pouli A, Kelaidi C, Kyrtsonis MC, Kotsopoulou M, Delimpasi S, Christoforidou A, Giannakoulas N, et al. Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients. Am J Hematol. 2014;89:803\u20138.","journal-title":"Am J Hematol"},{"key":"549_CR62","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/0360-3016(89)90008-4","volume":"16","author":"DA Frassica","year":"1989","unstructured":"Frassica DA, Frassica FJ, Schray MF, Sim FH, Kyle RA. Solitary plasmacytoma of bone: Mayo Clinic experience. Int J Radiat Oncol Biol Phys. 1989;16:43\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"549_CR63","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/hed.20821","volume":"30","author":"G Bachar","year":"2008","unstructured":"Bachar G, Goldstein D, Brown D, Tsang R, Lockwood G, Perez-Ordonez B, Irish J. Solitary extramedullary plasmacytoma of the head and neck\u2014long-term outcome analysis of 68 cases. Head Neck. 2008;30:1012\u20139.","journal-title":"Head Neck"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-017-0549-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,25]],"date-time":"2020-10-25T17:49:35Z","timestamp":1603648175000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-017-0549-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,16]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["549"],"URL":"https:\/\/doi.org\/10.1186\/s13045-017-0549-1","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,16]]},"assertion":[{"value":"26 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Jo Caers received honoraria from Amgen, Celgene, and Janssen-Cilag and research grants from Celgene. Elena Zamagni received honoraria from Janssen-Cilag, Celgene, BMS, and Amgen. Niels Abdilgaard received research grants from Takeda, Celgene, and Amgen and honoraria from Takeda, Celgene, and Janssen-Cilag. Xavier Leleu received honoraria from Janssen-Cilag, Celgene, Novartis, Sanofi, Amgen, Takeda, Pierre Fabre, Gilead, BMS, and Merck. Laura Rosinol received honoraria from Janssen, Celgene, Amgen, and Takeda. The other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"10"}}